Advertisement

Substance Use, Misuse and Dependence: Prevention and Treatment

A Cross-Journal Call for Papers

– PLOS Medicine Guest Editors –

Margarita Alegría

Steffanie Strathdee

Alexander Tsai

– PLOS ONE Guest Editors –

Philippe Bourgois

Daniel Ciccarone

Hannah Cooper

Carl Hart

Lindsey Richardson

 – Call for Papers for a PLOS Medicine Special Issue and PLOS ONE Collection –

 

Substance use and misuse affect people worldwide, of all ages and from all walks of life, resulting in a substantial burden of ill health and mortality, and presenting big challenges in prevention and treatment. PLOS Medicine is planning a special issue on this topic, and is now calling for research papers from the diverse communities that work to support people and populations affected by substance use and misuse. Our goal is to bring together clinicians and researchers from all the specialties involved in caring for people and communities impacted by substance use disorder, to stimulate research and strengthen the knowledge and expertise to combat the consequences of substance use and misuse. Submissions should be of broad interest to health practitioners, meet PLOS Medicine’s general criteria, and present research to help advance clinical practice or health policy

Articles must be submitted to PLOS Medicine by 7 June 2019. Questions and queries regarding the PLOS Medicine Special Issue can be sent to plosmedicine@plos.org

 

PLOS ONE is seeking rigorous primary research for an interdisciplinary Collection exploring the social, structural and environmental factors that contribute to risk or resilience for substance use disorders, determine their medical consequences and support recovery outcomes. We welcome contributions from the social sciences, public health and medicine that explore the environmental mechanisms that modulate individual responses to drugs and support favorable treatment outcomes by: 1) Assessing the impacts of drug use-relevant policies for human health, 2) Evaluating the effectiveness of novel structural prevention and treatment interventions and 3) Identifying and measuring the contribution of social, structural and environmental conditions to substance use disorder prevention, recovery and relapse.

Please find complete information about the PLOS ONE call for papers below

Articles must be submitted to PLOS ONE by 7 June 2019. Please send questions and queries regarding the PLOS ONE Collection to onecalls@plos.org

 
 

PLOS Medicine Special Issue Scope and Submission Instructions

Substance use and misuse affect people worldwide, of all ages and from all walks of life, resulting in a substantial burden of ill health and mortality, and presenting big challenges in prevention and treatment. PLOS Medicine is planning a special issue on this topic, and is now calling for research papers from the diverse communities that work to support people and populations affected by substance use and misuse. Our goal is to bring together clinicians and researchers from all the specialties involved in caring for people and communities impacted by substance use disorder, to stimulate research and strengthen the knowledge and expertise to combat the consequences of substance use and misuse. Submissions should be of broad interest to health practitioners, meet PLOS Medicine’s general criteria, and present research that helps to advance clinical practice or health policy. Areas of focus include:

  • Epidemiology of substance use, misuse, and dependence, and comorbid mental health disorders; risk factors including genetic, structural, interpersonal, individual, and life course influences; and sequelae for psychological and physical health.
  • Interactions between substance use and infectious diseases, including HIV and HCV.
  • Research on individual- and population-level approaches to prevention and treatment of substance use, including health services research and access to care, mechanisms of reward and addiction; modelling, social science, and implementation science approaches.
  • Methods for deployment and evaluation of policies and strategies for prevention, harm reduction, and treatment of substance use; solution-orientated research and approaches that integrate services for populations affected by substance use and other disorders.
  • Addressing substance use in key populations, including children and adolescents, those affected by the criminal justice system, and sexual minorities; factors contributing to the opioid syndemic and approaches to preventing and addressing the crisis.

 

Submission Instructions

Articles must be submitted to PLOS Medicine by June 7, 2019 at http://journals.plos.org/plosmedicine/s/submit-now. Submissions not selected for PLOS Medicine may be offered transfer to PLOS ONE, before or after peer review, with the prospect of inclusion in the accompanying PLOS ONE Collection.

Questions about the PLOS Medicine special issue can be directed to plosmedicine@plos.org

Authors submitting to  PLOS Medicine should specify the Special Issue, “Substance Use, Misuse, and Dependence: Prevention and Treatment” in their cover letter.

 

Meet the PLOS Medicine Guest Editors

Dr. Margarita Alegría 

Guest Editor, PLOS Medicine

Dr. Margarita Alegría is the Chief of the Disparities Research Unit at the Massachusetts General Hospital and a Professor in the Departments of Medicine and Psychiatry at Harvard Medical School.

 

Dr. Alegría’s research focuses on the improvement of health care services delivery for diverse racial and ethnic populations, conceptual and methodological issues affecting multicultural populations, and ways to bring the community’s perspective into the design and implementation of health services. Dr. Alegría is currently the Principal Investigator (PI) of three National Institutes of Health (NIH)-funded research studies: Building Community Capacity for Disability Prevention for Minority Elders; Mechanisms Underlying Racial/ Ethnic Disparities in Mental Disorders; and The Impact of Medicaid Plans on Access to and Quality of Substance Use Disorder (SUD) Treatment. She was also the PI of the NIDA-funded International Latino Research Partnership (ILRP), which tested a model of integrated care for Latino immigrants with co-occurring substance and mental health problems.

 

Dr. Alegria was one of the members of the National Academies of Science, Engineering and Medicine (NASEM) Committee studying the Health Effects of Marijuana: An Evidence Review and Research Agenda. This committee reviewed the existing evidence regarding the health consequences of using marijuana, including best treatments to address drug abuse and dependence. In addition, she was a reviewer for NASEM’s Report on Developing Evidence-Based Standards for Psychosocial Interventions for Mental Disorders.

 

Dr. Steffanie Strathdee

Guest Editor, PLOS Medicine

Dr. Steffanie Strathdee is an infectious disease epidemiologist renowned for her research on the intersection of HIV and drug use, having generated >600 scholarly publications. She is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego where she codirects the Center for Innovative Phage Applications and Therapeutics.  

Currently, she leads a multidisciplinary team researching HIV risk behaviors among people who inject drugs on the Mexico-US border where she developed one of the first interventions for female sex workers who inject drugs. In 2009, she and her team were awarded the Leadership Award in International Collaboration from the National Institute on Drug Abuse, who also granted her a MERIT award for her research in Tijuana.  Strathdee recently published a memoir entitled The Perfect Predator: A Scientist’s Race to Save Her Husband from a Deadly Superbug.

Dr. Alexander Tsai 

Guest Editor, PLOS Medicine

Dr. Alexander Tsai is a board-certified psychiatrist at the Massachusetts General Hospital and Associate Professor of Psychiatry at Harvard Medical School. Through his research, he seeks to understand how large-scale social forces such as violence, stigma, structural racism, and food insecurity conspire to undermine health and mental health among the poor and excluded. He has conducted patient-oriented research in sub-Saharan Africa for more than a decade, focusing on the intersection of HIV and mental health and disseminating his findings in more than 100 publications in peer-reviewed journals.

 

His team’s research study on structural racism, police killings, and population mental health was identified as one of the top 20 contributions to science in 2018 by the Clinical Research Forum. Prior to his appointment at Mass General, he completed a Robert Wood Johnson Health and Society Scholars postdoctoral fellowship at Harvard University and his residency training in general adult psychiatry at the University of California at San Francisco.

 

PLOS ONE Collection Scope and Submission Instructions

Substance use disorders (SUDs) are the result of complex interactions between genes, brain structure and function and environmental factors. Among the latter, social, physical, political, economic and cultural environmental factors, such as access and exposure to illicit substances, barriers to treatment, traumatic life events and neighborhood disadvantage, as examples, contribute to significant variation in the geographical distribution of substance use and substance use disorders across time and place. Given evolving policies relevant to the landscapes of substance use, treatment and recovery, research into the environmental mechanisms that modulate individual responses to drugs and support favorable treatment outcomes is imperative.

This call for papers for a PLOS ONE Collection convenes perspectives from the social sciences, public health and medicine to explore the social, structural and environmental factors that contribute to risk or resilience for SUDs, determine their medical consequences and support recovery outcomes. Contributions to this collection will: 1) Assess the impacts of drug use-relevant policies for human health, 2) Evaluate the effectiveness of novel structural prevention and treatment interventions and 3) Identify and measure the contribution of social, structural and environmental conditions to SUD prevention, recovery and relapse. The Guest Editors are Philippe Bourgois (University of California Los Angeles), Daniel Ciccarone (University of California San Francisco), Hannah Cooper (Emory University), Carl Hart (Columbia University) and Lindsey Richardson (University of British Columbia).

 Specifically, we welcome primary research papers on the following topics in particular:

  • Empirical research on the consequences of policies such as criminalization/legalization, risk/harm reduction, etc.
  • Research exploring connections between adverse life experiences and vulnerability to SUDs.
  • Analyses of historical patterns of drug use preference cycles, epidemics and other social and health sequelae that offer contemporary lessons.
  • Research exploring the relationship between drugs and violence, as mitigated by pharmacology, policies, markets, sociocultural forces, etc.
  • Work exploring differential vulnerability and resilience to drug-related harm by social position, class, race, gender, sexual orientation and intersectionality/dynamics of multiple disadvantage.
  • Studies of the role of sociocultural, logistical and political economic risk environments in promoting initiation and/or destructive/harmless trajectories of drug use.
  • Empirical work on the connections between drug markets, features of the built environment, etc. and SUDs, public health consequences and treatment outcomes.
  • Interventions to improve access to prevention and treatment services, integrate behavioral health care into general health services and reform healthcare and criminal justice systems to facilitate positive treatment outcomes.
  • Studies of drug–environment interactions in drug sensitization, responsiveness, preference and relapse.
  • Field studies in new landscapes of substance use, such as for example, supervised consumption facilities, clinical encounters in chronic pain management and the social contexts of use for electronic cigarettes and vaporizers, novel psychoactive substances, etc.
  • Economic analyses of drug-relevant policies and enforcement, community impacts, labor market effects, the role of economic conditions, health insurance coverage arrangements, etc.

Sharing the data underlying the studies’ findings will be a requirement of publication, per the PLOS data policy. As an interdisciplinary journal, PLOS ONE is open to all empirical research methods.

PLOS ONE will also consider submissions within the scope outlined by PLOS Medicine for inclusion in the Collection.

 

Submission Instructions

Articles must be submitted to PLOS ONE by June 7, 2019 at https://journals.plos.org/plosone/s/submit-now

Are you ready to submit or want to learn more about how the submission process works? To make it as easy as possible for our communities, we have all of our submission instructions posted online. Questions related to the PLOS ONE Collection can be sent to onecalls@plos.org

When submitting to the Collection, select the Article Type “Research Article” or “Clinical Trial” and enter “Substance Use, Misuse and Dependence: Prevention and Treatment” in the Collections field in the Additional Information section of the submission form. Please also specify that you are submitting to the Call for Papers “Substance Use, Misuse and Dependence: Prevention and Treatment” in your cover letter.

Learn how to format your work for  PLOS ONE  here​.

 

Meet the PLOS ONE Guest Editors

Philippe Bourgois

Guest Editor, PLOS ONE

Philippe Bourgois is Professor of Anthropology and Director of the Center for Social Medicine and Humanities in the Department of Psychiatry at the University of California, Los Angeles. His research focuses on incarceration, substance use disorders, violence, homelessness, mental illness, political economic determinants of health and HIV-prevention. He has published over 150 articles, books and edited volumes on these subjects including In Search of Respect: Selling Crack in El Barrio (Cambridge Press 1995), Righteous Dopefiend with Jeff Schonberg (UC Press 2009) and Violence in War and Peace co-edited with Nancy Scheper-Hughes (Wiley Blackwell 2004).

 

He received an AB from Harvard College (1978), MA degrees and a PhD from Stanford University (1980) and postdoctoral training at the École Normale Supérieure.

Daniel Ciccarone

Guest Editor, PLOS ONE

Daniel Ciccarone, MD, MPH, is Professor of Family and Community Medicine at the University of California, San Francisco. Dr. Ciccarone has been principal or co-investigator on numerous NIH sponsored public health research projects.  He is an internationally recognized scholar on the medical, public health and public policy dimensions of heroin and opioid use, risk and consequences. He is currently leading the Heroin in Transition study with its integrated multidisciplinary – ethnographic, economic and statistical modeling – aims to examine the recent rise in heroin use and the expanding diversity of heroin source-forms and illicitly-made synthetic opioids (e.g. fentanyls) and their relationship to sharp increases in illicit opioid-involved mortality and morbidity. He is Associate Editor for the International Journal of Drug Policy and recently edited an IJDP special issue on the “triple wave crisis” of opioids, heroin and fentanyl in the US.  

Dr. Dan Ciccarone, MD, MPH is a board certified clinician in Family Medicine and Addiction Medicine. He is a well-known educator and public speaker. He received his medical degree from State University of New York, Stony Brook (1987) and his MPH from University of California, Berkeley (1998). His residency took place at UCSF.

Hannah Cooper

Guest Editor, PLOS ONE

Hannah Cooper is the Rollins Chair of Substance Use Disorders Research at the Emory University Rollins School of Public Health, where she is Vice Chair in the Department of Behavioral Sciences and Health Education. Dr. Cooper co-directs of Prevention Science Core at the Emory Center for AIDS Research. The focus of Cooper’s research is on social determinants of substance use disorders and related harms.

She received a BA from Yale University (1993) and an SM (1998) and ScD (2003) from the Harvard School of Public Health. She completed a NIDA-funded postdoctoral fellowship at the National Development and Research Institute.

Carl Hart

Guest Editor, PLOS ONE

Carl Hart is the Chair of the Department of Psychology at Columbia University. He is also the Ziff Professor of Psychology in the Departments of Psychology and Psychiatry. Prof. Hart has published extensively in the area of neuropsychopharmacology. He is the author of the award-winning book, High Price: A Neuroscientist’s Journey of Self-Discovery That Challenges Everything You Know About Drugs and Society. He is also co-author of the textbook Drugs, Society and Human Behavior (with Charles Ksir).

Hart received a BS and MS from the University of Maryland, and a PhD in neuroscience from the University of Wyoming (1996). He completed postdoctoral work at UCSF, Yale and Columbia.

Lindsey Richardson

Guest Editor, PLOS ONE

Lindsey Richardson is an Assistant Professor of Sociology at the University of British Columbia and a Research Scientist, British Columbia Centre on Substance Use. She is a medical sociologist who specializes in socio-economic determinants of health among people who use illicit drugs and other vulnerable and marginalized populations. Her mixed-methods research links observational, intervention and research participation studies in efforts to critically increase understandings of the determinants and health consequences of socio-economic (in)security.

 

Richardson received a BA from the University of British Columbia (2001) and an M.Phil (2008) and D.Phil (2012) from the University of Oxford. Her postdoctoral work was supported by the Canadian Institutes of Health Research.

 

PLOS ONE Handling Editors

Arsham Alamian Stéphanie Baggio Leo Beletsky Cecilia Benoit
Sara Becker Sadie Boniface Robert Booth Adrian Bravo
Thomas Brown Viktor Burlaka Susan Busch Giuseppe Carrà
Carlos Castillo-Chavez Javier Cepeda Magdalena Cerda Ann Cheney
Kasey Claborn Benjamin Cook Karen Corsi Herbert Covington
Hans Crombag Joanne Csete Peter Davidson Christopher Doran
Mari-Lynn Drainoni Paul Draus Nicole Ennis Marica Ferri
Gabriele Fischer Patricia Freeman Daniel Fridberg Hugh Garavan
Angela Garcia Becky Genberg Tara Gomes Kerry Green
Joel Grube Matthew Gullo Wayne Hall Allison Hamilton
Lee Hoffer David Jarmolowicz Jayani Jayawardhana Hollis Karoly
Jesse Kaye Carl Latkin Victoria Manning Rodrigo Marín-Navarrete
Julie Maslowsky Jane Maxwell Bill McCarthy Kathryn McCollister
Jeremy Mennis Matthew Mimiaga Bronwyn Myers Victoria Ojeda
Mary Olmstead Lawrence Palinkas Dimitra Panagiotoglou Eugene Raikhel
Juliette Roddy Damaris Rohsenow Craig Ross Abby Rudolph
Christopher Salas-Wright Laura Schmidt Lion Shahab Dan Small
Laramie Smith Paul Spicer Lorenzo Stafford Jamila Stockman
John Strang Tamara Taggart Faye Taxman Bach Tran
Carla Treloar Carlos Trujillo Judith Tsui Kiyomi Tsuyuki
Katie Wang Wendee Wechsberg Abraham Weizman Daniel Werb
Brooke West Ryan Westergaard Reinout Wiers Thomas Wills
Nikki Wooten Ziming Xuan Siyan Yi Maria Zúñiga

Learn About PLOS

We’ve been around over 15 years now. Learn about our history, what we’re doing now, and the ways in which we’re working hard to change publishing for the better for scientists and for science.